List of bibliographic references
Number of relevant bibliographic references: 3.
List of associated KwdEn.i
Nombre de
documents | Descripteur |
|---|
| 3 | Adolescent |
| 3 | Adult |
| 3 | Aged |
| 3 | Drug Therapy, Combination |
| 3 | Female |
| 3 | Hepatitis C, Chronic (drug therapy) |
| 3 | Humans |
| 3 | Male |
| 3 | Middle Aged |
| 2 | Aged, 80 and over |
| 2 | Antiviral Agents (administration & dosage) |
| 2 | Antiviral Agents (therapeutic use) |
| 2 | Imidazoles (administration & dosage) |
| 2 | Polyethylene Glycols (therapeutic use) |
| 2 | Ribavirin (administration & dosage) |
| 2 | Young Adult |
| 1 | Antiviral Agents (adverse effects) |
| 1 | Benzofurans (administration & dosage) |
| 1 | Carbamates (administration & dosage) |
| 1 | Carbamates (adverse effects) |
| 1 | Carbamates (therapeutic use) |
| 1 | Double-Blind Method |
| 1 | Drug Administration Schedule |
| 1 | Genotype |
| 1 | Hepacivirus (classification) |
| 1 | Hepacivirus (genetics) |
| 1 | Hepatitis C, Chronic (complications) |
| 1 | Hepatitis C, Chronic (virology) |
| 1 | Heterocyclic Compounds, 4 or More Rings (administration & dosage) |
| 1 | Heterocyclic Compounds, 4 or More Rings (adverse effects) |
| 1 | Heterocyclic Compounds, 4 or More Rings (therapeutic use) |
| 1 | Imidazoles (adverse effects) |
| 1 | Interferon-alpha (administration & dosage) |
| 1 | Interferon-alpha (adverse effects) |
| 1 | Interferon-alpha (therapeutic use) |
| 1 | Interferons (therapeutic use) |
| 1 | Liver Cirrhosis (etiology) |
| 1 | Macrocyclic Compounds (administration & dosage) |
| 1 | Macrocyclic Compounds (adverse effects) |
| 1 | Macrocyclic Compounds (therapeutic use) |
| 1 | Polyethylene Glycols (administration & dosage) |
| 1 | Polyethylene Glycols (adverse effects) |
| 1 | Quinoxalines (administration & dosage) |
| 1 | RNA, Viral (analysis) |
| 1 | RNA, Viral (blood) |
| 1 | Recombinant Proteins (administration & dosage) |
| 1 | Recombinant Proteins (adverse effects) |
| 1 | Recombinant Proteins (therapeutic use) |
| 1 | Ribavirin (adverse effects) |
| 1 | Ribavirin (therapeutic use) |
| 1 | Sofosbuvir (administration & dosage) |
| 1 | Sofosbuvir (adverse effects) |
| 1 | Sofosbuvir (therapeutic use) |
| 1 | Sulfonamides (administration & dosage) |
| 1 | Sulfonamides (adverse effects) |
| 1 | Sulfonamides (therapeutic use) |
| 1 | Sustained Virologic Response |
| 1 | Treatment Failure |
| 1 | Treatment Outcome |
| 1 | Viral Load |
Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Asie/explor/AustralieFrV1/Data/Canada/Analysis
HfdIndexSelect -h $EXPLOR_AREA/Data/Canada/Analysis/Author.i -k "Eric Lawitz"
HfdIndexSelect -h $EXPLOR_AREA/Data/Canada/Analysis/Author.i \
-Sk "Eric Lawitz" \
| HfdSelect -Kh $EXPLOR_AREA/Data/Canada/Analysis/biblio.hfd
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Wicri/Asie
|area= AustralieFrV1
|flux= Canada
|étape= Analysis
|type= indexItem
|index= Author.i
|clé= Eric Lawitz
}}
| This area was generated with Dilib version V0.6.33.
Data generation: Tue Dec 5 10:43:12 2017. Site generation: Tue Mar 5 14:07:20 2024 |  |
